Warburg leads $171m funding in Chinese anti-tumour drug maker HaiHe Biopharma

Warburg leads $171m funding in Chinese anti-tumour drug maker HaiHe Biopharma

Source: Volodymyr Hryshchenko/Unsplash

HaiHe Biopharma, a Chinese biopharmaceutical firm that develops innovative anti-tumour drugs, has raised 1.2 billion yuan ($171 million) in a Series B round of financing led by Warburg Pincus.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter